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Abstract: Decreased circulating levels of free thiols (R-SH, sulfhydryl groups) reflect enhanced
oxidative stress, which plays an important role in the pathogenesis of cardiometabolic diseases.
Since hyperglycemia causes oxidative stress, we questioned whether plasma free thiols are altered
in patients with type 2 diabetes mellitus (T2DM) without cardiovascular disease or renal function
impairment. We also determined their relationship with elevated triglycerides and very low
density lipoproteins (VLDL), a central feature of diabetic dyslipidemia. Fasting plasma free thiols
(colorimetric method), lipoproteins, VLDL (nuclear magnetic resonance spectrometry), free fatty
acids (FFA), phospholipid transfer protein (PLTP) activity and adiponectin were measured in 79 adult
non-smoking T2DM subjects (HbA1c 51 ± 8 mmol/mol, no use of insulin or lipid lowering drugs),
and in 89 non-smoking subjects without T2DM. Plasma free thiols were univariately correlated with
glucose (r = 0.196, p < 0.05), but were not decreased in T2DM subjects versus non-diabetic subjects
(p = 0.31). Free thiols were higher in subjects with (663 ± 84 µmol/L) versus subjects without elevated
triglycerides (619 ± 91 µmol/L; p = 0.002). Age- and sex-adjusted multivariable linear regression
analysis demonstrated that plasma triglycerides were positively and independently associated with
free thiols (β = 0.215, p = 0.004), FFA (β = 0.168, p = 0.029) and PLTP activity (β = 0.228, p = 0.002),
inversely with adiponectin (β = −0.308, p < 0.001) but not with glucose (β = 0.052, p = 0.51). Notably,
the positive association of free thiols with (elevated) triglycerides appeared to be particularly evident
in men. Additionally, large VLDL were independently associated with free thiols (β = 0.188, p = 0.029).
In conclusion, circulating free thiols are not decreased in this cohort of non-smoking and generally
well-controlled T2DM subjects. Paradoxically, higher triglycerides and more large VLDL particles are
likely associated with higher plasma levels of thiols, reflecting lower systemic oxidative stress.
Keywords: adiponectin; free thiols; nuclear magnetic resonance spectroscopy; phospholipid transfer
protein activity; triglycerides; type 2 diabetes mellitus; large very low density lipoproteins
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1. Introduction
Reactive oxygen species (ROS) play essential roles in cell signalling and homeostasis [1,2].
Enhanced oxidative stress results from an imbalance between ROS production and antioxidant defence,
and is prominently involved in the pathogenesis of cardiometabolic disorders including diabetes
mellitus and atherosclerotic cardiovascular disease (CVD) [3]. Yet, current information with respect to
the extent to which systemic oxidative stress is enhanced in the diabetic state is still limited. It has
been well established that systemic ROS are increased under chronic hyperglycemic circumstances
leading to progression of beta-cell deterioration, insulin resistance and atherosclerosis [4]. Remarkably
however, it is not well known whether systemic oxidative stress is already enhanced in patients
with type 2 diabetes mellitus (T2DM) free of clinically manifest CVD, chronic kidney disease (CKD)
and albuminuria.
Thiols are organic compounds that are characterised by the presence of a sulfhydryl (R-SH) moiety [5].
R-SH groups are readily oxidised by ROS and other reactive species. The plasma concentration of free
thiols has been proposed to mirror systemic or local ROS production in such a way that a decline
in circulating free thiols indicates an enhanced oxidative tone [6,7]. In line with this supposition,
decreased plasma levels of free thiols have been observed among persons with CVD as compared to
healthy subjects [8,9]. In stable heart failure patients, higher levels of serum free thiols were associated
with favourable disease outcomes [7]. In hemodialyis patients, free thiols tend to be decreased in
the context of coinciding non-alcoholic fatty liver disease [10]. Furthermore, among renal transplant
recipients higher free thiols concentrations were associated with a beneficial cardiovascular risk profile
and a better patient and graft survival [11]. Recently, we demonstrated that in T2DM patients treated
in primary care with high circulating free thiols concentrations were associated with lower HbA1c
levels and less microvascular complications [12].
Elevated triglycerides, which are mainly carried by plasma very low density lipoproteins (VLDL),
are a central hallmark of diabetic dyslipidemia [13–15]. Despite intense study, the pathogenesis of
altered (hepatic) VLDL metabolism in the diabetic state has still not been fully elucidated. Among other
mechanisms, enhanced free fatty acid (FFA) and glucose availability contribute to increased hepatic VLDL
production in the context of T2DM [13,16,17]. Notably, the secretory control of VLDL particles by the liver
is a complex process, governed by endoplasmic reticulum (ER)/proteasome-associated degradation, post
ER pre-secretory proteolysis and receptor-mediated degradation, i.e., re-uptake mediated via low density
lipoprotein (LDL) receptors and proteoglycan abundancy [18–21]. Of particular note, in vitro studies
have revealed that intra-hepatic degradation of VLDL particles via post ER pre-secretory proteolysis
is triggered by intracellular ROS, coinciding with an enhanced oxidant tone [18,21,22]. Given the role
of the liver in the metabolism of fatty acids, glucose and other substrates it is not surprising that the
liver is crucially involved in generating ROS [23]. Additionally, since the plasma pool of free thiols is
mainly associated with albumin, it is conceivably that the liver contributes at least in part to systemic
ROS status. Combined, these findings make it plausible to hypothesise that systemic ROS status is linked
to triglyceride metabolism.
The present study was initiated, firstly, to discern the extent to which plasma levels of free thiols,
as a proxy of systemic ROS status, are altered in T2DM subjects without clinically manifest CVD disease
and preserved renal function. Secondly, we aimed to determine associations of plasma triglycerides
and VLDL particle characteristics with free thiols, thereby testing a hitherto unexplored relationship of
elevated triglycerides and systemic ROS.
2. Experimental Section
2.1. Subjects and Clinical Measurements
The study was performed at the University Medical Center Groningen (Groningen, the Netherlands)
and was approved by the local medical ethics committee (METC2002/174c). Caucasian participants of
European descent (aged >18 years) were recruited by advertisement. Written informed consent was
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obtained from all participants. T2DM had been diagnosed by primary care physicians using guidelines
from the Dutch College of General Practitioners (fasting plasma glucose≥7.0 mmol/L and/or non-fasting
plasma glucose≥11.1 mmol/L). Only T2DM patients who were treated with diet alone or in combination
with metformin and/or sulfonylurea were allowed to participate. T2DM subjects using insulin or other
glucose lowering medication were excluded. Further exclusion criteria were clinically manifest CVD,
renal insufficiency (estimated glomerular filtration rate (e-GFR) <60 mL/min/1.73 m2 and⁄or urinary
albumin >20 mg/L). e-GFR was calculated based on the serum creatinine-based Chronic Kidney Disease
Epidemiology Collaboration equation [24]. Subjects with liver disease (serum transaminase levels >2
times above the upper reference limit), pregnant women and subjects who were using lipid lowering
drugs were also excluded. Subjects who used other medications (except for oral contraceptives),
current smokers and subjects who used >3 alcoholic drinks daily were additionally excluded. Subjects
using anti-hypertensive medication were allowed to participate. Physical examination did not reveal
pulmonary or cardiac abnormalities. BMI (kg/m2) was calculated as weight (kg) divided by height (m)
squared. Waist circumference was measured as the smallest circumference between rib cage and iliac
crest. Blood pressure was measured after 15 min of rest at the left arm using a sphygmomanometer.
The participants were evaluated between 08.00 and 10.00 h after an overnight fast.
The metabolic syndrome (MetS) was defined according to NCEP-ATP III criteria [25]. Three or more
of the following criteria were required for categorization of subjects with MetS: waist circumference >
102 cm for men and > 88 cm for women; hypertension (blood pressure ≥130/85 mmHg or the use of
antihypertensive drugs); fasting plasma triglycerides ≥1.70 mmol/L; HDL cholesterol <1.00 mmol/L
for men and <1.30 mmol/L for women; fasting glucose ≥5.60 mmol/L. Insulin sensitivity was estimated
by homeostasis model assessment of insulin resistance (HOMA-IR) applying the following equation:
fasting plasma insulin (mU/L) × glucose (mmol/L)/22.5 [26].
2.2. Laboratory Measurements
EDTA-anticoagulated plasma samples were stored at −80 ◦C until analysis, except for plasma
glucose and glycated hemoglobin (HbA1c) levels which were measured shortly after blood collection.
Glucose was measured on an APEC glucose analyser (APEC Inc., Danvers, MA, USA).
High sensitivity C-reactive protein (hs-CRP) was measured by nephelometry with a threshold of 0.18
mg/L (BNII, Dade Behring). Glycated hemoglobin (HbA1c) was measured by high performance liquid
chromatography (Bio-Rad, Veenendaal, The Netherlands). Plasma total cholesterol and triglycerides were
assayed by routine enzymatic methods (Roche/Hitachi cat nos 11,876,023 and 11,875,540, respectively;
Roche Diagnostics GmBH, Mannheim, Germany). HDL cholesterol was measured with a homogeneous
enzymatic colorimetric test (Roche/Hitachi, cat no 04,713,214; Roche Diagnostics GmbH, Mannheim,
Germany). LDL cholesterol was calculated by the Friedewald formula if plasma triglycerides were
<4.5 mmol/L. Apolipoprotein B (apo B) was measured by immunoturbidimetry (Roche/Cobas Integra
Tina-quant, cat. Number 03032574, respectively; Roche Diagnostics, Roche Diagnostics GmBH, Mannheim,
Germany). Plasma free fatty acids (FFA) were measured with a kit from Wako Diagnostics (HR Series
NEFA-HR (2), Wako Chemicals GmbH, Neuss, Germany).
VLDL particle concentrations and VLDL subfractions were measured by nuclear magnetic
resonance (NMR) spectroscopy with the LP3 algorithm (LabCorp, Morrisville, North Carolina,
USA) [27,28]. VLDL particle classes and subfractions were quantified from the amplitudes of their
spectroscopically distinct lipid methyl group NMR signals. The diameter range estimate for VLDL
(including chylomicrons if present) was >60 nm to 29 nm, The VLDL particle concentration (VLDL-P)
was calculated as the weighted average of the respective lipoprotein subclasses. The intra-assay
coefficient of variation (CV) for VLDL-P amounts to 11.0%.
Plasma PLTP activity was assayed with a phospholipid vesicles-HDL system, using (14C)-labelled
dipalmitoyl phosphatidylcholine as described [29,30]. Briefly, plasma samples (1 µL) were incubated
with (14C)-phosphatidylcholine-labelled phosphatidylcholine vesicles and excess pooled normal HDL
for 45 min. at 37 ◦C. The method is specific for PLTP activity. Plasma PLTP activity levels vary linearly
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with the amount of plasma added to the incubation system. PLTP activity was related to the activity
in human reference pool plasma and was expressed in arbitrary units (AU; 100 AU corresponds to
13.6 µmol phosphatidylcholine transferred per mL per h). The intra-assay CV of PLTP activity was 5%.
Insulin was assayed by microparticle enzyme immunoassay (AxSYM insulin assay: Abbott
Laboratories, Abbott Park, IL, USA). Total adiponectin was measured by enzyme-linked immunosorbent
assay (Linco Research Inc., St. Charles, MO, USA, cat no EZHADP-61k). The provided by this assay
are strongly correlated with results obtained by enzyme-linked immunoassay measurement [31].
Plasma free thiols were assayed as described with minor modifications [32,33]. After thawing,
samples were four-fold diluted using 0.1 M Tris buffer (pH 8.2). Background absorption was measured
at 412 nm using the Varioskan microplate reader (ThermoScientific, Breda, the Netherlands), together
with a reference measurement at 630 nm. Subsequently, 20 µL 1.9 mM 5,5′-dithio-bis (2-nitrobenzoic
acid) (DTNB, Ellman’s Reagent, CAS no. 69-78-3, Sigma Aldrich Corporation, St. Louis, MO, USA)
was added to the samples in 0.1 M phosphate buffer (pH 7.0). After an incubation time of 20 min
at room temperature, absorbance was measured again. Final serum free thiol concentrations were
established by parallel measurement of an L-cysteine (CAS no. 52-90-4, Fluka Biochemika, Buchs,
Switzerland) calibration curve (range from 15.6 µM to 1000 µM) in 0.1 M Tris/10 mM EDTA (pH 8.2).
The intra-assay CV of free thiols amount to 6%.
2.3. Statistical Analysis
SPSS (IBM SPSS Statistics for Windows, Version 23.0. IBM Corp. Armonk, NY, USA) was used for
data analysis. The distributions of all variables were examined using histograms and Q-Q plots. Data
are expressed as mean (with standard deviation (SD)) or median (with interquartile range (IQR)) for
normally distributed and non-normally distributed data, respectively. Nominal data are presented as
n (with percentage (%)). Non-parametrically distributed data were loge transformed for statistical
analysis. Between-group differences in continuous variables were determined by unpaired T-tests.
Between-group differences in dichotomous variables were determined by χ2-analysis. Univariate
relationships were assessed using Pearson correlation coefficients. Multivariable linear regression
analysis was applied to disclose the independent contribution of variables. A p-value <0.05 (two-sided)
was used to indicate statistical significance.
3. Results
3.1. Study Population
The study population comprised 79 T2DM subjects and 89 non-diabetic subjects (Table 1).
Median diabetes duration was 5 (interquartile range (IQR) 4–6.5) years. Fourteen T2DM subjects used
metformin and 11 used sulfonylurea alone, whereas these drugs were used combined in 24 patients.
No other glucose lowering drugs were taken. The other T2DM subjects were given lifestyle advice
only. Anti-hypertensive medication (mostly angiotensin-converting enzyme inhibitors, angiotensin II
receptor antagonists and diuretics, alone or in combination) were taken by 33 T2DM subjects and by
none of the non-diabetic subjects (p < 0.001). Estrogens were used by two pre- and two postmenopausal
non-diabetic women. Other medications were not used.
As shown in Table 1, T2DM subjects were on average 4 years older than the non-diabetic subjects,
were more obese, had higher blood pressure, fasting plasma glucose and HbA1c levels, were more
insulin resistant and categorised with MetS more frequently. Sex distribution was not different between
the groups. e-GFR was similar in the groups.
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Table 1. Clinical and laboratory characteristics in 79 subjects with Type 2 diabetes mellitus (T2DM) and




(n = 89) p-Value
Age (years) 59 ± 9 55 ± 9 0.011
Sex (men/women) 49/30 49/40 0.45
Metabolic syndrome (yes/no) 54/25 21/68 <0.001
Systolic blood pressure (mm Hg) 144 ± 20 131 ± 19 <0.001
Diastolic blood pressure (mm Hg) 87 ± 9 83 ± 11 0.007
BMI (kg/m2) 28.6 ± 4.8 25.9 ± 3.9 <0.001
Waist (cm) 100 ±13 89 ± 9 <0.001
Glucose (mmol/L) 8.9 ± 2.3 5.6 ± 0.7 <0.001
HbA1c (mmol/mol) 51 ± 8 39 ± 5 <0.001
Insulin (mU/L) 10.8 (7.2,15.3) 6.5 (4.7,8.6) <0.001
HOMA-IR (mU mmol/L2/22.5) 3.96 (2.37,6.64) 1.57 (1.09,2.29) <0.001
e-GFR (mL./min/1.73 m2) 91 ± 13 87 ± 14 0.12
Total cholesterol (mmol/L) 5.38 ± 0.96 5.74 ± 0.99 0.022
Non-HDL cholesterol (mmol/L) 4.12 ± 1.04 4.25 ± 1.06 0.44
LDL cholesterol (mmol/L) 3.27 ± 0.85 3.53 ± 0.89 0.06
HDL cholesterol (mmol/L) 1.26 ± 0.38 1.49 ± 0.40 <0.001
Triglycerides (mmol/L) 1.70 (1.17,2.30) 1.31 (0.89,1.95) 0.034
ApoB (g/L) 0.95 ± 0.23 0.96 ± 0.23 0.55
VLDL-P (nmol/L) 69.5 (46.2,88.7) 61.8 (51.6,101.6) 0.83
Large VLDL (nmol/L) 7.1 (2.7,11.1) 3.5 (2.0,9.4) 0.019
Medium VLDL (nmol/L) 28.9 (14.9,41.3) 25.3 (13.2,44.8) 0.86
Small VLDL (nmol/L) 27.7 (16.8,43.9) 33.9 (21.2,44.5) 0.076
FFA (mmol/L)) 0.35 ± 0.12 0.30 ± 0.12 0.001
PLTP activity (AU) 104 ± 11 94 ± 10 <0.001
Adiponectin (mg/L) 14.3 (10.7,26.3) 20.1 (14.9,43.0) <0.001
Free Thiols (µmol/L) 645 ± 102 630 ± 78 0.31
Data are expressed in means ± SD, medians (interquartile range) or numbers. Abbreviations: ApoB: apolipoprotein
b; BMI: body mass index; e-GFR: estimated glomerular filtration rate; FFA: free fatty acids; HbA1c: glycated
hemoglobin; HDL: high density lipoproteins; LDL: low density lipoproteins; PLTP: phospholipid transfer protein;
VLDL: very low density lipoproteins: VLDL-P: very low density particle concentration. Differences between
subjects with and without T2DM were determined by T-tests (using loge transformed values in case of not-normally
distributed data) and by χ2 tests, where appropriate. VLDL particle concentrations and VLDL subfractions were
measured in 66 subjects with diabetes and in 56 subjects without diabetes. LDL cholesterol was calculated by the
Friedewald formula in 75 T2DM subjects and in 87 non-diabetic subjects.
3.2. Comparison of Laboratory Variables between Subject Categories
Plasma total cholesterol was lower in T2DM subjects, which was due to lower HDL cholesterol.
Triglycerides were higher in T2DM subjects but non-HDL cholesterol, LDL cholesterol and apolipoprotein
b (ApoB) levels were not different between the groups. The total VLDL particle concentration was not
different between the groups, but large VLDL particles were increased, whereas small VLDL particles
tended to be decreased in T2DM subjects. Plasma FFA and PLTP activity were elevated, whereas
adiponectin was decreased in T2DM subjects (Table 1).
In all subjects combined, plasma free thiol concentrations were higher in men (n = 98, 655± 87µmol/L)
than in women (n = 70, 614 ± 91 µmol/L, p = 0.003). Free thiols were not different between T2DM and
non-diabetic subjects (Table 1), and were not significantly related to diabetes duration (r = −0.136,
p = 0.23). Free thiols were also not different in T2DM subjects compared to non-diabetic subjects after
exclusion of T2DM subjects using glucose lowering medication (n = 20, 600 ± 109 µmol/L, p = 0.14),
antihypertensive medication (n = 44, 652 ± 110 µmol/L, p = 0.21) or both classes of drugs (n = 15,
598 ± 117µmol/L, p = 0.17). Likewise, free thiols were also not different between subjects with MetS
(n = 75, 643 ± 89 µmol/L) and without MetS (n = 93, 633 ± 92 µmol/L, p = 0.49). Free thiols were
not different in subjects with elevated glucose (p = 0.39), enlarged waist circumference (p = 0.44) or
elevated blood pressure (p = 0.29) compared to subjects who did not fulfil these MetS criteria (data not
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shown). Notably, free thiols were higher in subjects with elevated triglycerides (n = 71, 663 ± 84 µmol/L,
p = 0.002) or with low HDL cholesterol (n = 45, 661 ± 84 µmol/L, p = 0.042) compared to subjects who
did not fulfil these MetS criteria (triglyceride criterion: 619 ± 91 µmol/L; HDL cholesterol criterion
(629 ± 92 µmol/L).
3.3. Univariate Correlations
In all subjects combined, univariate analysis showed that plasma free thiols were inversely
correlated with age, HDL cholesterol, FFA and adiponectin, and positively with glucose, e-GFR,
non-HDL cholesterol, triglycerides, VLDL particle concentration and large-and medium-sized VLDL
particles (Table 2, panel A). Comparable correlations were observed in T2DM subjects separately
(Table 2, panel B and panel C). The univariate correlations of plasma free thiols with triglycerides and
with large VLDL particles are shown in Figure 1, panel A and panel B, respectively. In non-diabetic
subjects, free thiols were correlated positively with total cholesterol, non-HDL cholesterol, triglycerides
and ApoB, and inversely with FFA and adiponectin (Table 2, panel C). Neither in all subjects combined
nor in T2DM subjects and non-diabetic subjects separately were free thiols correlated with blood
pressure, BMI, waist circumference and PLTP activity (Table 2, panel A, B and C). In addition, in all
subjects combined, PLTP activity was correlated positively with triglycerides (r = 0.325, p < 0.001) and
FFA (r = 0.162, p = 0.036; data not shown). Similar correlations of PLTP activity with triglycerides were
found in T2DM subjects and non-diabetic subjects separately (data not shown).
Table 2. Univariate relationships of plasma free thiols with clinical and laboratory variables in all
subjects combined (n = 168, panel A), Type 2 diabetic (T2DM) subjects (n = 79, panel B) and in
non-diabetic subjects (n = 89, panel C).
(A) All Subjects
(n = 168) Free Thiols
(B) T2DM Subjects
(n = 79) Free Thiols
(C) Non-Diabetic Subjects
(n = 89) Free Thiols
Age −0.183 * −0.297 ** −0.098
Systolic blood pressure −0.053 −0.074 −0.093
Diastolic blood pressure 0.031 0.145 −0.119
BMI 0.059 −0.012 0.108
Waist 0.131 0.057 0.172
Glucose 0.196 * 0.262 * 0.012
HbA1c 0.151 0.186 −0.013
Insulin 0.095 0.022 0.131
HOMA-IR 0.141 0.106 0.132
e-GFR 0.213 ** 0.271 * 0.144
Total cholesterol 0.084 −0.057 0.281 **
Non-HDL cholesterol 0.168 * 0.056 0.314 **
LDL cholesterol 0.034 −0.148 0.247 *
HDL cholesterol −0.232 ** −0.302 ** −0.137
Triglycerides 0.285 *** 0.290 ** 0.260 *
ApoB 0.129 0.063 0.349 ***
VLDL-P 0.204 * 0.247 * 0.138
Large VLDL 0.266 ** 0.333 ** 0.129
Medium VLDL 0.234 ** 0.333 ** 0.081
Small VLDL −0.013 0.007 −0.020
FFA −0.187 * −0.210 −0.224 *
PLTP activity 0.034 −0.096 0.133
Adiponectin −0.261 *** −0.259 * −0.247 *
Pearson correlation coefficients are shown. Non-parametrically distributed data are loge transformed. * p < 0.05;
** p≤ 0.01: *** p≤ 0.001. Abbreviations: ApoB: apolipoprotein B; BMI: body mass index; e-GFR: estimated glomerular
filtration rate; FFA: free fatty acids: HbA1c: glycated hemoglobin; HDL: high density lipoproteins; LDL: low density
lipoproteins; PLTP: phospholipid transfer protein; VLDL: very low density lipoproteins; VLDL-P: very low density
particle concentration. VLDL particle concentrations and VLDL subfractions were measured in 66 subjects with
diabetes and in 56 subjects without diabetes. LDL cholesterol was calculated by the Friedewald formula in 75 T2DM
subjects and in 87 non-diabetic subjects.
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Figure 1. Univariate correlations of plasma free thiols with plasma triglycerides (panel A; 79 type 2
d abetic subjects and 89 subjects without diab tes) and with very l rge very low density lipoprot in
(VLDL) (pan l B; 66 type 2 diabetic subjects and 58 subjects without diabet s). Legend: closed symbols
represent subjects without diabete ; open symbol repre ent subjects with type 2 iabet s. The l g
transformed data (i.e., triglyceride and large very low d sity lipoproteins) were used. The back
me sur s are shown on the Y-axis. Pearson correlati n coefficients: fre thiols with
iglycerides; all s bjects, r = 0.285, p < 0.001; Type 2 diabetic subjects, r = 0.290, p = 0.01; subjec s
w thout diabetes, r = 0.260, p = 0.014. Free thiols with larg VLDL: all subjects, r = 0.266, p = 0.003;
Type 2 diabetic subjects, r = 0.333, p = 0.006; subjects without diabetes, r = 0.138, p = 0.31.
In all men combined (n = 98), plasma free thiols were inversely correlated with age and adiponectin,
and positively with HOMA-IR, e-GFR, triglycerides, VLDL particle concentration and large VLDL
particles (Table S1). In all women combined (n = 70), plasma free thiols were not significantly correlated
with any of the variables listed in Table 2 (Table S1).
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3.4. Multivariable Linear Regression Analyses
Multivariable linear regression analyses were first carried out to disclose the association of free
thiols with the diabetic state when taking account of age and sex. In this analysis, free thiols were not
significantly related to the presence of T2DM after adjustment for age and sex (p = 0.159; data not
shown). Next, we examined the extent to which plasma free thiol concentrations were independently
associated with the individual MetS components. This analysis showed that free thiols were positively
associated with elevated triglycerides but not with other MetS components (Table 3). Furthermore, free
thiols were positively associated with male sex (Table 3). In an additional analysis, now also including
e-GFR, there was no independent association of free thiols with e-GFR (β = 0.122, p = 0.20), while the
relationship with elevated triglycerides remained significant (β = 0.209, p = 0.011). In a sex-stratified
analysis, plasma free thiols were positively associated with elevated triglycerides in men (Table S2).
In women, plasma free thiols were not significantly related to any of the individual MetS components
(Table S2).
Table 3. Multivariable linear regression analysis demonstrating independent associations of plasma
free thiols with age, sex and individual metabolic syndrome components in 168 subjects (79 Type 2
diabetic subjects and 89 non-diabetic subjects).
β p-Value
Age −0.205 0.011
Sex (men versus women) 0.213 0.005
Elevated glucose 0.074 0.35
Elevated blood pressure −0.069 0.40
Enlarged waist 0.021 0.80
Elevated triglycerides 0.200 0.015
Low HDL cholesterol 0.060 0.47
Abbreviations: β: standardised regression coefficient; HDL: high density lipoproteins.
Given the association between triglycerides and free thiols, we next determined whether this
relationship remained when taking account of the diabetic state instead of the MetS criterion of
elevated plasma glucose. In this analysis, plasma triglycerides were positively associated with free
thiols (β = 0.271, p < 0.001) after adjustment for age (β = 0.01, p = 0.89), sex (β = 0.001, p = 0.97) and
the presence of diabetes (β = 0.245, p = 0.059). Subsequently, we tested whether other variables
that were univariately related to plasma triglycerides or free thiols including PLTP activity, FFA and
adiponectin (Table 2). Plasma glucose was also included in these models in view of its univariate
correlation with free thiols. In this multivariable model, with plasma triglycerides as dependent variable,
plasma triglycerides were positively and independently associated with free thiols, FFA and PLTP
activity, and inversely with adiponectin but not with glucose (Table 4). These associations remained
significant after further adjustment for the use of sulfonylurea, metformin and antihypertensive drugs
(data not shown). Similar associations of plasma triglycerides with free thiols, FFA, PLTP activity
and adiponectin were found with HbA1c or the presence of T2DM instead of plasma glucose (data
not shown).
In sex-stratified analysis, it was found that plasma triglycerides were positively associated
with free thiols, FFA, PLTP activity and inversely with adiponectin in men (Table S3). In women,
plasma triglycerides were positively associated with PLTP activity and tended to be inversely associated
with adiponectin, but the association with free thiols was not significant (Table S3).
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Table 4. Multivariable linear regression analysis demonstrating independent associations of plasma
triglycerides with age, sex, free thiols, free fatty acids, phospholipid transfer protein activity and
adiponectin and glucose in 168 subjects (79 Type 2 diabetic subjects and 89 non-diabetic subjects).
β p-Value
Age −0.044 0.55
Sex (men versus women) 0.016 0.84
Free thiols 0.215 0.004
FFA 0.168 0.029
PLTP activity 0.228 0.002
Adiponectin −0.308 <0.001
Glucose 0.052 0.51
Triglycerides and adiponectin are loge transformed. Abbreviations: β: standardised regression coefficient; FFA: free
fatty acids: PLTP phospholipid transfer protein.
Finally, we determined the association of free thiols with VLDL subfractions. Large-sized VLDL
particles were positively and independently associated with free thiols and FFA, and inversely with
adiponectin (Table 5, panel A). Medium-sized VLDL particles tended to be associated positively with
free thiols and were inversely associated with adiponectin (Table 5, panel B). Small-sized VLDL particles
were not independently associated with any of these variables (Table 5, panel C). In sex-stratified
analyses, the independent association of large VLDL particles with plasma free thiols did not reach
statistical significance in men (β = 0.184, p = 0.14) or in women (β = 0.188, p = 0.14; data not shown).
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Table 5. Multivariable linear regression analysis demonstrating independent associations of very low density lipoprotein (VLDL) subfractions with age, sex, free thiols,
free fatty acids, PLTP activity, adiponectin and glucose in 122 subjects (66 Type 2 diabetic subjects and 56 non-diabetic subjects). Panel A, Large VLDL; panel B,
medium VLDL, panel C, small VLDL.
A Large VLDL B Medium VLDL C Small VLDL
β p-Value β p-Value β p-Value
Age −0.042 0.630 0.036 0.71 0.021 0.82
Sex (men versus women) 0.074 0.440 0.049 0.65 −0.156 0.17
Free thiols 0.188 0.029 0.176 0.067 −0.023 0.82
FFA 0.242 0.008 −0.014 0.91 −0.157 0.41
PLTP activity 0.147 0.094 0.075 0.45 −0.066 0.52
Adiponectin −0.294 0.002 −0.243 0.021 −0.047 0.67
Glucose 0.097 0.320 −0.052 0.630 0.029 0.80
VLDL subfractions and adiponectin are loge transformed. Abbreviations: β: standardised regression coefficient; FFA: free fatty acids; PLTP phospholipid transfer protein; VLDL: very low
density lipoproteins.
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4. Discussion
In this cohort of non-smoking and in general appropriately controlled T2DM subjects, we report
that circulating levels of free thiols are still maintained. In the current study, we excluded T2DM
subjects who smoked, those with clinically manifest CVD or impaired renal function as well as subjects
using insulin or lipid lowering medication. Therefore, the present findings suggest that decreased free
thiol concentrations, as a proxy of enhanced systemic oxidative stress, are unlikely to represent an early
feature of relatively moderate chronic hyperglycemia. Second, we report here for the first time that
plasma triglycerides and in particular large VLDL particles are positively and independently related to
free thiols in multivariable linear regression analysis in which we accounted for age, sex, glucose (or
alternatively the presence of diabetes), FFA, PLTP activity and adiponectin. Notably, the association of
free thiols with triglycerides appeared to be particularly evident in men. We consider this novel and
seemingly surprising finding to agree with the hypothesis that systemic ROS status may impact on
triglyceride metabolism. As a mechanism, we postulate that this association may at least in part be
attributable to an effect of hepatic ROS to inhibit VLDL release in the bloodstream.
To underscore the lack of effect of the presence of T2DM on plasma free thiol concentrations
as observed in the present study, we also carried out sensitivity analyses after exclusion of T2DM
subjects using any glucose lowering medication, antihypertensive medication or both classes of drugs.
Again, it was found that plasma free thiols were not decreased in the cohort of T2DM subjects studied.
Our results can be compared with another study on thiols in T2DM by Pasaoglu et al. [34]. In a
small study among 40 T2DM subjects (20 newly diagnosed and 20 treated using oral blood glucose
lowering therapy only) and 20 non-diabetic subjects they demonstrated lower plasma total thiol levels
among persons with T2DM as compared to control subjects (605 ± 36 versus 665 ± 60 µmol/L) [34].
Since a negative correlation between HbA1c and thiols has been reported [12], it should be taken
into account that T2DM subjects in their study were poorly regulated with an average HbA1c of
74 ± 30 mmol/mol and of 78 mmol/mol, in newly diagnosed and medically treated T2DM subjects,
respectively. Recently, we measured free thiols in a population of 929 T2DM outpatients treated in
primary care [12]. In this cohort, we found significant multivariable associations between free thiols
and the presence of macrovascular complications, age, BMI, diastolic blood pressure, HbA1c (all
inverse associations), male sex, diabetes duration and use of platelet aggregation inhibitors (all positive
associations). In addition, there was (modest) additional value for free thiols for risk prediction of
long-term complications. In agreement with these and previous results, we observed in the current
study that free thiols declined with ageing and were higher in men than in women [11,12], whereas we
also confirmed a positive relationship with e-GFR at least in univariate regression analysis [11].
Data concerning the relationship of ROS status and circulating free thiols in particular on fasting
plasma triglycerides in humans is scarce. In the aforementioned study amongst primary care treated
T2DM patients, there was no association between plasma free thiols and triglyceride concentrations
in multivariable analysis [12]. It should be noted, however, that in this population, samples were
non-fasting and 80% of the patients used cholesterol-lowering medication. Amongst persons with type
1 diabetes, no association between plasma free thiols and triglycerides was present [35]. Interestingly,
in mice receiving a high-saturated fat diet, the intake of the anti-oxidative ‘thiol donor’ n-acetyl cysteine
decreased plasma triglyceride concentrations possibly by lowering the activity and mRNA of malic
enzyme, fatty acid synthase and 3-hydroxy-3-methylglutaryl coenzyme A reductase [36,37].
In the present study, we assessed the relationship of plasma free thiols with triglycerides not only
when taking account of FFA and glucose, which are well-known substrates of hepatic triglyceride
synthesis [13,16], but also of PLTP activity and adiponectin. We found that plasma triglycerides as well
as large VLDL particles were associated with FFA levels in agreement with the contention that FFA
provide an important source for hepatic VLDL synthesis [13,17,38]. Although hepatic overproduction of
large VLDL particles, a central feature of diabetic dyslipidemia, has been proposed to be to an important
extent driven by hyperglycemia [16], plasma triglycerides were not independently associated with
glucose, which we ascribe to the modestly elevated fasting glucose levels in the current T2DM cohort.
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Importantly, studies in mice with genetic Pltp deficiency have revealed that PLTP is able to
promote the hepatic secretion of apoB-containing lipoproteins [39], effect which was subsequently
found to be attributable to the ability of PLTP to regulate ROS-dependent intracellular degradation
of newly assembled VLDL [40,41]. In humans, plasma PLTP activity has repeatedly been shown
to be associated with plasma triglyceride metabolism [42–45]. Moreover, genetic variation in Pltp
associates with lipid traits including triglycerides [46]. Plasma triglycerides were indeed positively
associated with PLTP activity in the current study. Of note, this relationship was independent from its
positive association with plasma free thiols. In establishing the association of plasma triglycerides
with free thiols, we also accounted for plasma adiponectin in multivariable regression analysis.
Adiponectin may stimulate hepatic fatty acid oxidation and ameliorate the development of hepatic
steatosis [47]. In line, we previously reported an inverse relationship of plasma adiponectin with alanine
aminotransferase [48]. Importantly, adiponectin has been implicated in preventing mitochondrial
dysfunction, and hence, may inhibit ROS production in vitro, possibly by promoting uncoupling
protein 2 expression [47]. Of note, we observed an inverse univariate relationship of plasma free thiols
with adiponectin, thereby providing a rationale to adjust for plasma levels of this adipokine when
evaluating the association of plasma triglycerides with free thiols. Still, plasma triglycerides as well as
large VLDL particles remained associated with plasma free thiols when considering adiponectin in
multivariable linear regression analysis. Taken together, our current study provides support for the
hypothesis that ROS status may influence triglyceride metabolism even independent of plasma glucose,
FFA, PLTP activity and adiponectin. However, since plasma free thiols were not different between the
currently studied T2DM and non-diabetic subjects, it seems unlikely that alterations in ROS status
explain to a considerable extent why plasma triglycerides and large VLDL particle concentrations
are increased in T2DM. Additionally, the mechanisms responsible for apparent sex-differences in the
association of free thiols with triglycerides are not yet clear. Plasma free thiols are higher in men than
in women as confirmed in the current study [11,12]. Additionally, fasting plasma triglycerides may
also be higher in men (as derived from [49]). Among other explanations it seems, therefore, plausible
that there is less between subject variation in free thiols and triglycerides in women compared to men,
which could to some extent blunt the strength of the correlation between free thiols and triglycerides
in women.
Our findings are relevant from a diagnostic perspective. In transplant patients and heart failure
patients the systemic redox status may have predictive power for outcome [7,11]. In recent work
we also showed that the systemic level of free thiols is a better reflection of disease activity in
inflammatory bowel disease than faecal calprotectin, the classical marker [50]. However, free thiols
are also receptive to therapeutic modulation, and can therefore be considered a potential therapeutic
target for therapy [51,52]. In clinical trials, a cysteine derivative N-Acetylcysteine directly reduces
disulfide bonds and act thereby as a glutathione (GSH) precursor [52]. Although promising, therapeutic
results are inconsistent and these compounds may be effective in selected patients with low free
thiol concentrations.
Several other methodological aspects of our study need to be discussed. First, we carried
out a cross-sectional study. For this reason, cause-effect relationships cannot be established with
certainty, nor can we exclude the possibility of reversed causation. Hence, we cannot exclude that
alterations in triglyceride metabolism could affect the balance between ROS production and antioxidant
defence. In this vein, a scenario is also possible whereby increased hepatic substrate availability
leads to enhanced β-oxidation which in turn affects hepatic ROS production. Second, the sample
size of the current study was rather limited, possibly masking relatively modest associations between
variables of interest. Third, only diabetic subjects who did not use lipid lowering medication were
allowed to participate, thereby avoiding confounding due to effects of statins on triglycerides and
PLTP activity [53,54]. As a consequence, it is likely that T2DM subjects with mild dyslipidemia
were preferentially included. Fourth, only non-smokers participated. This exclusion criterion was
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implemented in order to avoid effects of smoking on systemic ROS [55]. Moreover, cigarette smoking
affects lipid metabolism, including elevations in PLTP activity [56].
5. Conclusions
Plasma free thiols, which mirror the redox status, are still maintained in generally adequately
controlled non-smoking T2DM subjects, without clinically manifest cardiovascular disease or chronic
kidney disease indicating limited organ and cell damage. Higher fasting plasma triglycerides and
increased large VLDL particles concentrations are inversely associated with free thiols, raising the
possibility that enhanced oxidative stress could be paradoxically implicated in less severe dyslipidemia.
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